Skip to main content

Risk factors for failure of long-term dutasteride add-on treatment to alpha-adrenergic antagonist for patients with lower urinary tract symptoms and benign prostatic enlargement



To identify the clinical factors resulting in the failure of dutasteride add-on treatment to alpha-adrenergic antagonist for patients with lower urinary tract symptoms and benign prostatic enlargement (BPE).


We retrospectively surveyed the patient cohort who had been enrolled in the study of dutasteride add-on treatment to alpha-adrenergic antagonist from December 2009 to November 2011. Treatment failure was defined as receiving surgery for BPE or requiring intermittent catheterization or permanent bladder catheter for urinary retention or huge postvoid residual urine. Clinical parameters before dutasteride treatment were compared between the successful and failed group.


Of 92 patients, 23 (25%) were defined as treatment failure at 7–109 months (mean: 38 months) after dutasteride add-on treatment. In the failed group, the patient’ age was younger (71.6  ±  6.8 vs 75.4  ±  8.4, p = 0.033), prostatic volume (PV) was larger (76  ±  41 vs 49  ±  26 ml, p = 0.005), voiding efficiency was lower (54  ±  27 vs 68  ±  24%, p = 0.045) and bladder outlet obstruction index was higher (73  ±  30 vs 48  ±  30, p = 0.015). The cox proportional-hazards model indicated that only intravesical prostatic protrusion (IPP) was associated with treatment failure. Non-failure rate at 3 years after dutasteride add-on treatment was 89% with patients of IPP < 13 mm versus 51% with those of IPP ≥ 13 mm (p < 0.001).


IPP ≥ 13 mm is the risk factor resulting in the failure of dutasteride add-on treatment to alpha-adrenergic antagonist. This kind of information should be provided to the patients early in the clinical practice so that they could consider the necessity of BPE surgery in the long run.

This is a preview of subscription content, access via your institution.

Fig. 1


  1. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57: 123–131

  2. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434–441

    Article  Google Scholar 

  3. Takamori H, Masumori N, Kamoto T (2017) Surgical procedures for benign prostatic hyperplasia: a nationwide survey in Japan, 2014 update. Int J Urol 24:476–477

    Article  Google Scholar 

  4. Wada N, Kita M, Hashizume K, Matsumoto S, Kakizaki H (2013) Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study. Neurourol Urodyn 32:1123–1127

    CAS  Article  Google Scholar 

  5. Wada N, Hashidume K, Tamaki G, Kita M, Iwata T, Matsumoto S, Kakizaki H (2012) Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker: its effect on overactive bladder. Act Urol Jpn 58:475–480

    Google Scholar 

  6. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R (2007) The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 10:149–154

    CAS  Article  Google Scholar 

  7. Niu Y, Ge R, Hu L, Diaz C, Wang Z, Wu CL, Olumi AF (2011) Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate 71:1317–1324

    CAS  Article  Google Scholar 

  8. Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL et al (2015) Age and obesity promote methylation and suppression of 5α reductase 2: implications for personalized therapy of benign prostatic hyperplasia. J Urol 194:1031–1037

    Article  Google Scholar 

  9. Kang PM, Kim YJ, Seo WT et al (2019) Correlation between 5-α reductase type 2 protein expression and methylation of 5-α reductase type 2 promotor gene of benign prostatic hyperplasia. World J Urol 37:709–718

    CAS  Article  Google Scholar 

  10. Gu X, Na R, Huang T, Wang L, Tao S, Tian L et al (2013) SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists. J Urol 190:615–619

    CAS  Article  Google Scholar 

  11. Matsukawa Y, Kato M, Funahashi Y, Majima T, Yamamoto T, Gotoh M (2017) What are the predicting factors for the therapeutic effects of dutasteride in male patients with lower urinary tract symptoms? Investigation using a urodynamic study. Neurourol Urodyn 36:1809–1815

    CAS  Article  Google Scholar 

  12. Hirayama K, Masui K, Hamada A, Shichiri Y, Masuzawa N, Hamada S (2015) Evaluation of intravesical prostatic protrusion as a predictor of dutasteride-resistant lower urinary tract symptoms/benign prostatic enlargement with a high likelihood of surgical intervention. Urology 86:565–569

    Article  Google Scholar 

  13. Yoshida T, Kinoshita H, Yoshida K, Mishima T, Taniguchi H, Yanishi M, Komai Y, Yasuda K, Sugi M, Matsuda T (2016) Intravesical prostatic protrusion as a predicting factor for the adverse clinical outcome in patients with symptomatic benign prostatic enlargement treated with dutasteride. Urology 91:154–157

    Article  Google Scholar 

  14. Lim KB, Ho H, Foo KT, Wong MYC, Fook-Chong S (2006) Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. Int J Urol 13:1509–1513

    Article  Google Scholar 

  15. Madersbacher S, Klingler HC, Djavan B, Stulnig T, Schatzl G, Schmidbauer CP, Marberger M (1997) Is obstruction predictable by clinical evaluation in patients with lower urinary tract symptoms? Br J Urol 80:72–77

    CAS  Article  Google Scholar 

  16. Wadie BS, Ibrahim EH, de la Rosette JJ, Gomha MA, Ghoneim MA (2001) The relationship of the International Prostate Symptom Score and objective parameters for diagnosing bladder outlet obstruction. Part I: when statistics fail. J Urol 165:32–34

    CAS  Article  Google Scholar 

  17. Masumori N, Furuya R, Tanaka Y, Furuya S, Ogura H, Tsukamoto T (2010) The 12-year symptomatic outcome of transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the urodynamic findings before surgery. BJU Int 105:1429–1433

    Article  Google Scholar 

  18. Wada N, Kikuchi D, Tateoka J, Abe N, Banjo H, Tsuchida M, Hori J, Tamaki G, Kita M, Kakizaki H (2019) Long-term symptomatic outcome after transurethral resection of the prostate: a urodynamics-based assessment. Int J Urol 26:1071–1075

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Naoki Wada.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wada, N., Abe, N., Miyauchi, K. et al. Risk factors for failure of long-term dutasteride add-on treatment to alpha-adrenergic antagonist for patients with lower urinary tract symptoms and benign prostatic enlargement. Int Urol Nephrol 54, 31–36 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Alpha-adrenergic antagonist
  • Benign prostatic hyperplasia
  • Dutasteride
  • Outcome